Foundation for Neglected Disease Research

  • Program
  • Target
  • Hit to
  • Lead
  • Regulatory
    GLP Toxicology
  • Clinical Trial
    Phase 1
  • Clinical Trial
    Phase 2
  • Clinical Trial
    Phase 3
An inhalation peptide drug candidate (NF1001/PM181108) in partnership with National Centre of Oceanic and Antarctic Research (NCAOR) Goa, for Rx of MDR/XDR TB: We have a natural product derived peptide antibiotic with excellent in vitro and in vivo activity in mouse and guinea pig TB infection models. Peptide candidate kills TB through a novel mode of action by inhibiting ribosome associated GTPase activity blocking protein translation. Several in vivo, inhalation combination studies with Isoniazid and Rifampicin or second line drugs revealed superiority of peptide containing combinations. It reduced bacterial load in mouse lung tissue infected with drug resistant Mtb to below LOD in 1 month in combination with amikacin, moxifloxacin, ethambutol and pyrazinamide as compared to 3 months required for this combination without peptide antibiotic. Thus, this peptide has significant potential for treatment of MDR TB, shortening duration of therapy and sterilization. The drug candidate is at a stage of GLP toxicology preceding to filling IND.
A novel anti TB drug candidate (TBA-7371) that targets mycobacterial DprE1cell wall target required for Arabinan synthesis. Our partner, TB Alliance has initiated the Phase 1 clinical trial of TBA-7371.
Inhibitors of Enoyl ACP reductase (InhA) of M.tuberculosis: InhA/ACP reductase is a clinically validated target of Isoniazid and Ethambutol. FNDR has well-characterised series of compounds with strong in vitro target inhibition profile and pharmacokinetics. This asset offers opportunity to develop direct inhibitors of InhA/ACP reductase, with a different mechanism of action. These compounds are expected to work on mycobacterial strains resistant due to catG mutations that account for majority of INH resistance. The asset is ready for lead optimization.
  • Pre Clinical
  • Clinical
FNDR is the recipient of a grant award: Grand challenges in Tuberculosis (GC-TBC) entitled “Diagnosis of Tuberculosis using host and bacterial biomarker signatures”. This is funded by United States Agency for International Development (USAID), Biotechnology Industrial Research Assistance Council (BIRAC) and Bill and Melinda Gates Foundation (BMGF), and implemented by ICICI Knowledge Park (IKP) Hyderabad. FNDR also holds complete rights to a patent that has been filed for a biomarker based diagnostic for detection of TB (Itaconic acid and Tuberculostearic acid)
FNDR holds a patent for azo dyes that can be used to the detection and/or quantification of itaconic acid for the diagnosis of gestational diabetes mellitus and preterm labour and also methods of using the azo dyes to react with itaconic acid and methods of using the product of the reaction between the azo dyes and itaconic acid, to detect quantify itaconic acid in samples of interest. This is currently under the clinical stage.
FNDR was awarded the NESTA-Longitude Prize under BIRAC Discovery award funding for the project – Biomarker based diagnostic to differentiate between bacterial and viral infections

FNDR holds patents on several assets individually or jointly with other partners:

  1. A novel anti TB drug candidate that targets mycobacterial DprE1cell wall target required for Arabinan synthesis. A series of azaindoles is at the stage of Phase 1. FNDR holds equal right (50:50) in partnership with Global Alliance for Tuberculosis (GATB).
  2. Inhibitors of Enoyl ACP reductase (InhA) of tuberculosis, a clinically validated target of Isoniazid and Ethambutol. This asset offers possibility of developing direct inhibitors of mycobacterial ACP reductase. FNDR holds 100% rights on this asset.
  3. FNDR holds right in partnership in a patent estate of 2 patents for the treatment of TB that is ready for advanced safety/toxicology studies followed by clinical development with NCAOR (50:50). Currently, looking for funding/development partners to establish GLP toxicology.
  4. FNDR has identified a series of potent and novel anti Visceral Leishmania agents based on Eugenol. A provisional patent has been filed based on these finding to protect the use of such derivatives for the treatment of visceral leishmaniasis.
  5. FNDR has identified compounds of a novel chemical class of for the treatment of Tuberculosis. A provisional patent application covering composition of matter was filed for this class of compounds.

Present and Past collaborators

Anthem Biosciences, Bangalore
Global Alliance for TB, New York
IMTECH, Chandigarh
Medicines for Malaria Venture, Geneva, Switzerland
National Center for Antarctic and Ocean Research (NCAOR), Goa
National University of Singapore
SASTRA University, Tanjavur
St. John’s Hospital, Bangalore
Vellore Institute of Technology, Vellore